Spruce Biosciences Updates ATM Agreement, Strengthens Leadership Team

Spruce Biosciences ( (SPRB) ) has provided an update.

On March 9, 2026, Spruce Biosciences entered a new open market sale agreement with Jefferies to allow at-the-market issuances of common stock under an existing shelf registration, replacing a prior 2022 sales agreement and providing additional financial flexibility without obligating the company to sell shares. The company also reported 2025 results showing a narrowed net loss of $39.0 million on sharply reduced R&D spending, secured up to $50 million in growth capital from Avenue Capital in January 2026, and said its year-end 2025 cash of $48.9 million plus the new facility should fund operations into early 2027.

Operationally, Spruce highlighted positive February 2026 Type B meetings with the FDA indicating that existing TA-ERT clinical and natural history data may support an accelerated approval strategy, reinforcing its plan to file a biologics license application in the fourth quarter of 2026 for MPS IIIB, which currently has no approved therapies. To support a potential launch, the company appointed veteran rare disease commercial executive Dale (Corwin) Hooks as chief commercial officer effective March 9, 2026, expanded its regulatory and clinical leadership team, presented encouraging long-term TA-ERT data at WORLDSymposium, and noted that recent reauthorization of the U.S. Rare Pediatric Disease Priority Review Voucher program could enhance the asset’s strategic value if approved.

The most recent analyst rating on (SPRB) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Spruce Biosciences stock, see the SPRB Stock Forecast page.

Spark’s Take on SPRB Stock

According to Spark, TipRanks’ AI Analyst, SPRB is a Neutral.

The score is primarily held down by weak financial performance (large losses, heavy cash burn, and declining revenue) and bearish-to-neutral technical signals (below key short/intermediate moving averages with negative MACD). Recent financing events modestly improve liquidity/runway, but they do not offset the current loss profile and cash burn.

To see Spark’s full report on SPRB stock, click here.

More about Spruce Biosciences

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, including tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo syndrome type B (MPS IIIB). The company is listed on the Nasdaq Capital Market under the ticker SPRB and is building commercial infrastructure in anticipation of potential product launches.

Average Trading Volume: 38,831

Technical Sentiment Signal: Sell

Current Market Cap: $59.8M

For an in-depth examination of SPRB stock, go to TipRanks’ Overview page.